Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
December 03, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
November 25, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
November 22, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay
Optical Imaging Agent Market Expected to Expand at 8.1% CAGR, Reaching US$ 3,533.2 Million by 2034 | Fact.MR Report
November 21, 2024 07:30 ET
|
FACT.MR
Rockville, MD, Nov. 21, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global optical imaging agent market is estimated to reach a...
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
November 04, 2024 07:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
October 18, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an additional manufacturing and supply...
Radiopharmaceuticals Market to Expand at a Stellar 9.8% CAGR through 2031 | SkyQuest Technology
October 16, 2024 09:30 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Radiopharmaceuticals Market will attain a value of USD 8 billion by 2031, with a CAGR of 9.8% over the forecast period...
Radiopharmaceuticals Market Size Projected to Soar to USD 16.6 Billion by 2032 with 10.4% CAGR – SNS Insider
October 04, 2024 09:00 ET
|
SNS Insider pvt ltd
Pune, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Radiopharmaceuticals Market Analysis: According to SNS Insider, the Radiopharmaceuticals Market Size was estimated at USD 5.0 billion in 2023 and is...
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
October 01, 2024 07:45 ET
|
Curium
Curium partners with PeptiDream for clinical development, regulatory filing, and commercialization of prostate cancer therapies in Japan.
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
September 19, 2024 05:22 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry...